← Vericel Corporation (VCEL) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Vericel Corporation (VCEL)
Biological Products, (No Diagnostic Substances) · market cap $2.0B · as of 2026-07-16
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-05 (est.)
Earnings
Pipeline
3
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Vericel Corporation (VCEL) is a commercial-stage biologics company with 357 employees and a $2.35B market cap, focused on cell therapy products. Its lead asset MACI (autologous cultured chondrocytes on porcine collagen membrane) is in Phase 3 for chondral and articular cartilage defects, while ixmyelocel-T is in Phase 3 for ischemic dilated cardiomyopathy (IDCM). The company has been revenue-positive and is approaching consistent profitability, with the next near-term event being Q2 2026 earnings on July 30.
The catalyst path
- 2026-11-05 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| MACI | Phase 3 | Chondral Defect |
| autologous cultured chondrocytes on porcine collagen membrane | Phase 3 | Articular Cartilage Defect |
| ixmyelocel-T | Phase 3 | Ischemic Dilated Cardiomyopathy (IDCM) |
Price & technical context
3-month
-16.0%
6-month
+21.1%
12-month
+25.3%
52-wk range
$29.34–$48.31
vs 50-day MA
-6.6%
vs 200-day MA
+3.1%
Realized vol
41.4%
Max drawdown
-52.5%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for VCEL (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.